can be utilized to discover changes in expression of pleural proteins that might have diagnostic value. The objective of this study was to detect protein profiles that could be used to identify malignant pleural mesothelioma with surface enhanced laser desorption/ionization time-of-flight (SELDI-TOF) mass spectrometry (MS). Pleural effusions were collected from patients with confirmed mesothelioma (n = 41) and from patients with effusions due to other causes ([n = 48] cancerous and non-cancerous). Samples were fractionated using anion exchange chromatography and bound to different types of ProteinChip array surfaces. All samples were also subjected to other commercially available immunoassays (human epididymes protein 4 [HE4], osteopontin [OPN], soluble mesothelin-related proteins [SMRP], and the cytokeratin 19 fragment [CYFRA 21-1]). Peak intensity data obtained by SELDI-TOF were subjected to classification algorithms in order to identify potential classifier peaks.
Introduction
Malignant mesothelioma (MM) is a highly aggressive neoplasm arising from the mesothelial surfaces of the pleural cavities and less frequently in the peritoneal cavities, the pericardium, or the tunica vaginalis testis (1). Imaging techniques have proven useful when MM is suspected due to the presence of pleural effusion (in 95% of the patients at some time during the course of the disease) combined with a history of occupational or secondary asbestos exposure. Patients who present with large pleural effusions will have a thoracentesis to confirm the presence of cancerous cells using (electron) microscopic and/or immunohistochemistry (IHC) techniques. In spite of intensive research efforts, no single immunostain exists that is entirely conclusive for MM, and for most commercially available antibodies recorded in the literature both the diagnostic value of each individual one or their various combinations in immunohistochemical panels are still under debate (2, 3) . Only in 32% of the cases diagnostic cytological evidence is found in the pleural fluid (4) . Main problem areas in the pathologic assessment of specimens from patients with a clinical suspicion of MM are the distinction with adeno carcinoma, metastatic sarcoma or sarcomatoid carcinoma, Technology in Cancer Research & Treatment, Volume 8, Number 5, October 2009 and distinction between malignant and benign mesothelioma, even by experienced cytopathologists (5). Therefore, more objective methods of obtaining a specific diagnosis have been advocated: correlation of specific protein expression levels were investigated in body fluids for osteopontin (6), mesothelin (7) , and soluble mesothelin-related proteins (SMRP) (8) .
The objective of this study was to detect novel protein profiles in pleural effusions that could be used as biomarker(s) to further differentiate MM from other pulmonary disease states. Surface enhanced laser desorption/ionization timeof-flight (SELDI-TOF) mass spectrometry (MS) was used with different Protein Chip arrays (IMAC30, H50, and CM10) in a total of 89 pleural effusion samples. Using an artificial intelligence classification algorithm, several novel biomarkers were selected to facilitate separation of MM from other cancers or inflammatory conditions. Given the probable rise in the worldwide incidence of this disease during the next few years, increasing the sensitivity and specificity of diagnostic testing for mesothelioma for individual cases will be very relevant.
Materials and Methods

Mesothelioma Patients and Controls
Pleural fluid was collected after informed consent from patients who presented with large pleural effusions. Pleural effusions were due to the following conditions: 41 patients with mesothelioma and 48 patients with effusions due to other causes (non-infective inflammatory exudates (n = 3), transudates (n = 3), a still unknown cause (n = 2), and other malignancies (n = 40)). The characteristics of the patients are reported in Table I . All mesothelioma patients were cytologically or histologically proven by experienced pathologists and many of the patients had a past exposure to asbestos. The histologic subtype of the mesothelioma samples were 51.2 % epithelioid subtype (21 pt); 36.6% of the biphasic (epithelioid/sarcomatoid) subtype (15 pt) and 12,2% belonging to the sarcomatoid subtype (5 pt). The non-mesothelioma cancers with pleural involvement can be divided into carcinoma (28 metastasis of distant tumor and 6 non-small cell lung carcinoma), sarcoma (3), lymphoma (2), and melanoma (1). We obtained written informed consent from all participants. The study was approved by the Medical Ethics Review Committee (METC) of the Erasmus MC, Rotterdam, The Netherlands. Irrespective of cause, all effusions were collected, processed, and stored in the same way. Pleural fluid was gently aspirated and collected in sterile tubes without anticoagulant or other additives. Pleural cells were removed by centrifugation at 400 g for 10 min at 4°C and supernatant was then subjected to a second centrifugation at 3000 g for 20 min at 4°C and the resulting supernatant was stored in aliquots at -80°C until further analysis. No infectious agents were observed in the pleural fluid and bacterial cultures were negative in all cases.
Antibodies and proteins
All antibodies and calibrator proteins were purchased from US Biologicals (Swamp-scott, MA, USA): goat anti-human apolipoprotein (Apo) CI (cat # A2299-61); human Apo CI purified from plasma (cat # A2290-60). ProteinA HyperD beads were purchased from BioSepra (Cergy-Saint-Christophe, France). 
Protein Expression Profiling
Pleural effusions were fractionated using anion exchange chromatography according to the protocol described by Gilbert et al., (9) . Briefly, pleural effusion was applied to Q HyperD F anion exchange resin, and six fractions were eluted using a descending stepwise pH gradient. Each of these fractions was applied to IMAC30, H50, and CM10 ProteinChip arrays. The arrays were read in PBSIIc ProteinChip reader, a time-lag focusing, linear, laser desorption/ionization-time of flight mass spectrometer. The instrument was set to measure in the range between mass-to-charge ratio (m/z) 1000 en m/z 15,000. Data were collected averaging 65 laser shots with laser intensity 200, detector sensitivity 6, and a focus lag time of 636 ns. External calibration of the instrument was performed using the All-in-1 peptide molecular peptide molecular mass standard (Bio-Rad Laboratories) on the day of measurement. Peak error was set as 100 ppm. All samples were normalized according to the total ion current and qualified mass peaks (signal-to-noise ratio > 5) with m/z between 1000 and 15,000 Da automatically detected. A peak threshold of 5% was selected for all spectra. A second-pass peak selection was performed by choosing a mass window within 0.3% (signal-to-noise ration > 2), and estimated peaks were added. ProteinChip software was used to subtract elevated baselines caused by chemical noises by a smooth to the spectrum's local minima, and then normalized to the total ion current. Spectra with normalization factors > 2 or < 0.5 were excluded from further analysis.
Data Analysis
Data preprocessing was performed in CiphergenExpress version 2.1. Multivariate analysis was performed using PAM (Prediction Analysis for Microarrays) (10). In this study, we used the feature selection functionality. Permutation testing was performed to determine the threshold for calling a peak significant based on random class assignments. Hothorn et al., (11) described the detailed algorithm about permutation tests used in this study. The optimal peaks were analyzed by ROC (Receiving Operating Characteristics Curve) analysis. Principal component analysis was performed to visualize the separating power of the best peaks. All analyses were performed using the statistical package R and SPSS (SPSS, Inc., Chicago, IL).
Antibody-capture Based Confirmation of Biomarker Candidates' Identities
The appropriate antibodies were coupled to Protein A Hyper D beads (BioSepra Inc., Marlboro, MA, USA) as follows: the antibody was diluted to 0.05 mg/ml in PBS. In a well of a 96 well 0.45 µm filter plate, a 50 µl aliquot of diluted antibody was mixed with 2 µl of Protein A Hyper D beads for 50 min at room temperature (RT). The beads were washed 3 times with 200 µl of PBS in the filter plate wells by means of a vacuum manifold. The antibody-coupled beads were then used to specifically capture proteins from samples: 10 µl of pleural effusion was diluted with 40 µl of PBS, added to the beads, and incubated for 30 min on a microtiter plate shaker (form 21, amplitude 7) (MicroMix5, Diagnostic Products Corporation, Gwynedd, UK). After the incubation step the beads were washed three times with 200 µl of PBS, two times with 200 µl (50 mM Tris, pH 7.5, 1 M urea, 0.2% CHAPS, 0.5 M NaCl), three times with 200 µl of PBS and finally once with 200 µl of 5 mM Hepes pH 7.4. Finally the proteins were eluted with 30 µl of 0.1 M acetic acid. Per sample a volume of 3 µl eluate fraction was profiled on NP20 ProteinChip arrays by incubation on-spot in a total volume of 10 l (water added until final volume) for 30 min in a humid chamber, followed by two on-spot water washes, an air-drying step and two consecutive applications of 1 µl sinapinic acid ([SP] dissolved in a 400 µl volume of 50% acetonitrile, 0.5% TFA). To ascertain that the captured protein indeed is Apo CI the outcome of the eluate fraction analyses was compared to corresponding volumes of the depleted pleural effusion samples and of the non-depleted effusion samples when analyzed on the NP20 surface type. Five (out of fifty) µl volumes of the depleted fraction and two (out of ten) µl fractions of the non-depleted (original) effusion volume were analyzed in comparison to 3 out of 30 µl of the captured target.
Enzyme Immunoassays
Unless noted otherwise, all immunoassays were carried out following manufacturer's recommendations. Pleural fluid samples were thawed at RT and mixed by vortexing prior to use in the assays. SMRP levels in pleural effusions were determined using the MESOMARK assay from Fujirebio Diagnostics (Malvern, PA, USA). Osteopontin (OPN) was measured using a sandwich ELISA kit from IBL (Japan). HE4 was measured by sandwich ELISA using a RUO kit and CYFRA 21-1 was measured using the RIA both from Fujirebio Diagnostics.
Statistical Analysis
Data are expressed as mean ± SD. Comparisons between groups were made using the one-way ANOVA and Mann-Whitney U-test for independent samples. Data were log-transformed before analysis. A two-tailed p-value < 0.05 was considered significant. Statistical analysis were performed using the statistical package R and SPSS (SPSS, Inc., Chicago, IL, USA). (Table I) . Supernatants of pleural effusions were subjected to immunoassays to quantitate the level of osteopontin (OPN), human epididymes protein 4 (HE4), cytokeratin 19 fragment (CYFRA 21-1), and the soluble mesothelin-related protein (SMRP) to determine their use in addition to the pathologist's findings. Results from these immunoassays were logarithmically transformed and compared using the independent t-test and presented in a boxand-whisker plot showing the median, quartiles and outliers ("o" = outlier [> 1.5x interquartile range (IQR), " * " = extreme [ 3x IQR]) ( Figure 1a ). The differences in expression levels of OPN and HE4 in mesothelioma versus non-mesothelioma samples were not statistically significant. CYFRA 21-1 and SMRP assays were able to differentiate the group of mesothelioma samples from non-mesothelioma pleural effusions (p < 0.001, t-test). The outlier in the CYFRA 21-1 assay was obtained from a mesothelioma patient that had underwent 4 times a thoracentesis, all samples displayed the same high content in CYFRA 21-1 (outlier in HE4 is the same sample).
ROC curve analysis for MM versus non-MM showed an AUC of 0.736 (0.630-0.841 [95% confidence interval]) and 0.860 (0.782-0.938) for CYFRA 21-1 and SMRP, respectively ( Figure 1b) . The sensitivities and specificities were dependent of the clinical cut-off values. For example, a sensitivity of 83% and specificity of 74% was obtained with a SMRP value of 7.05 nM/L but using 14 nM/L the sensitivity and specificity altered into 73% and 80%.
Supernatants of pleural effusion samples were then subjected to anion exchange chromatography, generating six fractions containing subsets of the effusions' protein contents. Each fraction was applied to three ProteinChip array types (IMAC30, H50, and CM10), resulting in 18 fraction-array combinations. Peaks detected by the Expression Difference Mapping module in CiphergenExpress were analyzed using the software package Prediction Analysis of Microarrays (PAM) to determine peaks with the greatest between-class variance while minimizing within-class variance. The five peaks with the best discriminating power identified by PAM were at mass-to-charge ratios (m/z) 6614 (found on CM10, fraction 1), m/z 6626 (found on H50, fraction 1), m/z 6656 (found on CM10, fraction 1), m/z 6821 (found on CM10, fraction 1), and m/z 8799 (found on H50, fraction 6) (Table II) . Figure 2 displays the logarithmically transformed expression levels for each protein peak in box-and-whisker plots.
Comparison between groups had P values < 0.005 for each protein. Table III shows the expression level for each of these peaks the mean and within-class variance in the mesothelioma subject group and the group suffering pleural effusions due to other causes.
ROC curve analysis showed an AUC of 0.741 (0.636 -0.845 [95% confidence interval]) for protein peak 6614 Da and using a cut-off value of m/z 132, its sensitivity and specificity were found to be 76% and 69%, respectively (Figure 3) .
Each of the five proteins found by SELDI analysis was downregulated in the mesothelioma group. The proteins are highly correlated to each other, with correlation coefficients between 0.5 and 0.95. Based on previous experience with peaks at these m/z values eluting from these fractions and binding to these arrays (12), we hypothesized that the first four peaks were Apo CI or adducts of Apo CI, and that the m/z 8799 peak was Apo AII (Table I) .
To confirm the identity of the candidate markers, hypothesized as isoforms or adducts of Apo CI, we performed immunoprecipitation followed by analysis with mass spectrometry (immuno-MS). For this purpose negative control antibodies and anti-Apo CI antibodies were coupled to Protein A Hyper D beads and the antibodies' captured target antigens were eluted. Analyses of the eluates showing molecular weights (m/z values corresponding to the calibrator proteins' experimental molecular weights confirmed the observed markers' identities as Apo CI (Figure 4) . The observed identity similarity between captured target and calibrator protein was further confirmed by the partial removal of the target antigen in the depleted pleural effusions and the presence of the target antigen in the original non-depleted sample ( Figure 5 ). In addition to the expected molecular weight for both the calibrator protein and the observed marker candidate, the calibrator protein and the capture experiments also revealed a common quadruplet peak cluster around 6.4 kDa for the Apo CI target. The 6.6 kDa and 6.4 kDa peak clusters captured do represent Apo CI and the postulated Apo CI form lacking the aminoterminal Thr-Pro sequence. The glutathionylated 6.8 kDa Apo CI sinapinic acid adduct (+ ~190 Da) was not visible in these immuno-MS spectra. In contrast to obvious expression level differences for the Apo CI isoforms in the 6.6 kDa cluster between the MM and non-MM group the expression level difference for the peaks in the 6.4 kDa cluster are less pronounced considering selected patients with high (non-MM patients 80, 78 and 100) and low (MM patients 53, 52 and 9) extremes for the Apo CI 6.6 kDa cluster peaks ( Figure 6 ). Figure 7A shows the separating power of the two main contributing vectors in a principal component analysis and Figure 7B shows scatter plots for the m/z 6614 peak and the m/z 8799 peak, of the Apo CI and Apo AII proteins respectively.
Patients with low levels of both the Apo CI and Apo AII protein signals were exceedingly likely to have MM versus other conditions (non-MM). However, because of the high correlation in amount of the two proteins, it was unfeasible to construct multivariable models encompassing both proteins or any other protein features in the generated SELDI-TOF spectra, that had significantly better classifying ability than either of the two proteins alone.
Discussion
As the presence of pleural effusion may be indicative for MM, removal of fluid or a biopsy is normally performed to confirm the presence and type of cancerous cells. However, conclusive diagnosis of MM or the differential diagnosis from other cancer forms with similar histological characteristics has proven difficult since exclusive immunostainings have been lacking. Research into novel biomarkers has been performed for several years with the specific aim to find a correct and early diagnosis of MM (13).
In addition to the proteins present in serum and pleural effusion of MM patients reported on in literature (6-8), we have pursued to investigate the presence of alternative proteins in pleural effusions collected during thoracenteses. Pleural fluid can provide a valuable matrix for measurements of molecules reflecting the subject's condition or a specific systemic response. By means of SELDI-TOF MS, we investigated pleural effusion samples (n = 89) of both pleural mesothelioma diagnosed subjects (n = 41) and of 48 subjects with other malignancies, lymphatic abnormalities, and transudative pleural effusions caused by renal failure and pulmonary embolism.
For several of the SELDI-TOF MS spectral features (6614 Da, 6656 Da and 6821 Da in pleural effusion fractions 1 applied to CM10 surface type; 6626 Da in effusion fraction 1 and the 8799 Da feature in effusion fraction 6 on the H50 surface type) the average intensities in the MM group showed to be decreased significantly in comparison to the pleural effusions caused by other disorders (Tables II and III) .
Experience from earlier protein identification work for similar spectral features in serum (combinations of molecular weight labels and ProteinChip array surface type) suggested that the molecules were Apolipoprotein (Apo) CI and Apo AII isoforms (12). Confirmation of that hypothesized identity was obtained by means of SELDI-based antibody capture approaches using an anti-Apo CI antibody method. Apo CI was successfully captured from pleural effusions from selected subjects (n = 6) of both the pleural mesothelioma (n = 3) and other cause (n = 3) exudative effusion groups. The additionally captured 6.4 kDa peak is postulated to be Apo CI lacking the amino-terminal Thr-Pro dipeptide (14). A similar Apo CI peptide was also observed and identified in serum samples by means of SELDI-TOF MS (15). Further investigation would be required to understand the origin of this Apo CI form: it could either be due to exoproteolytic digestion of the full-length 6.6 kDa Apo CI during the sample handling or alternatively could be caused by cleavage of the signal sequence prior to polypeptide secretion. The latter explanation might be acceptable: this 6.4 kDa form is also present in the capture of the purified calibrator protein dilution in PBS, where no exoprotease activity is added as part of a lysate. In addition, there is also a significant difference of the 6.4 kDa to 6.6 kDa peak ratio in the MM vs. non-MM; where the MM effusions show mainly the 6.4 kDa peak, the non-MM pleural effusions show an equal amount of both the 6.4 kDa N-terminally cut form and the intact 6.6 kDa peptide form.
We did not intend to provide a complete coverage of the whole proteome of human pleural effusions. The sets of proteins we found in this study were not known to be cancer associated, and expected proteins such as SMRP were not detected, indicating that this affinity-based biomarker discovery platform gives a bias towards relatively highly-abundant proteins in unfractionated samples. Validation of the apolipoprotein findings, developing an immunoassay and testing it in a randomized prospective study will have to demonstrate the usefulness of apolipoproteins in the diagnosis of MM in the future. The Apo CI forms in pleural effusions perform reasonably as single biomarkers for separation of pleural mesothelioma from other pleural effusions: their performance is characterized by areas under ROC curves (AUC) between 0.688 and 0.755, with a sensitivity of 76% and specificity of 69%. As single markers, Apo CI's isoforms may currently not provide improved prediction success for MM cases but might be considered as candidates in future multi-marker panels. Several publications have already reported on pathology situations where Apo CI was detected as significantly up regulated or down regulated. Apo CI has been reported as one of the panel markers in postoperative serum samples with predictive power for metastatic relapse in high-risk primary breast cancer patients receiving adjuvant chemotherapy (16). Therefore, in the pleural mesothelioma context, it could be worthwhile to engage in a prospective follow-up study to determine the expression levels for selected Apo CI isoforms and other potential diagnostic markers in body material samples of subjects with pleural MM versus other effusion causes.
Steps towards positive diagnosis of pleural malignant mesothelioma could comprise the combined analyses of Apo CI isoforms and other commercially available immunoassays in the fluid part of the pleural effusion. Therefore, we measured the expression of human epididymes protein 4 (HE4), human osteopontin (OPN), soluble mesothelin-related proteins (SMRP), and the cytokeratin 19 fragment (CYFRA 21-1) in all pleural effusion samples. Others have described the over expression of OPN and HE4 in mesothelioma compared to benign lung conditions (6, 17) and in other malignancies (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) . OPN so far has been described as a marker protein positively characterizing pleural MM in immunohistochemical stainings on the cellular components of pleural effusions and in a free form in the serum of mesothelioma patients (6). This study showed that OPN does not provide a useful parameter for the differential diagnosis between MM and other malignancies in contrast to CYFRA 21-1 (AUC in the ROC curve of 0.736). The use of CYFRA 21-1 for diagnosing mesothelioma has been described for a long time (28-30). Mesothelin is aberrantly expressed by several tumor types (31). Mesothelin and the corresponding soluble form SMRP gives rise to megakaryocyte potentiating factor (MPF) (32-34). The biologic functions of mesothelin and SMRP remain speculative, but pleural SMRP levels are significantly higher in mesothelioma in comparison to benign lesions and pleural metastases (8). However, the caveat that the serum levels measured might only partially mirror the SMRP levels in the pleural cavity is corroborated by Scherpereel and co-workers' results showing that the levels of SMRP are typically higher in the pleural fluids in comparison to the corresponding serum samples (35) , and that therefore the discrepancy between the AUC for serum SMRP (AUC = 0.693) differentiating between mesothelioma and pleural metastasis is lower than based on the pleural SMRP values (AUC = 0.793).
In this study, ROC curve analysis for MM versus non-MM showed an AUC of 0.860 (with a sensitivity of 83% and specificity of 74% for an SMRP value of 7.05 nM/L) demonstrating the usefulness of SMRP as diagnostic marker. Serum SMRP levels have been described as tumor-size related and to decrease upon surgical cytoreduction interventions (7, 8, 36, 37) . This leads to the suggestion that analysis of SMRP in the pleural effusion fluid might be preferable for positive primary diagnosis while the serum SMRP values might contain an opportunity as a treatment monitoring tool in a follow-up population. Recent publications confirm our results that the MESOMARK assay is useful for the diagnosis of mesothelioma (38, 39) .
In conclusion, we have found that the expression level of Apo CI is decreased significantly in pleural effusions of subjects diagnosed with malignant mesothelioma when comparing with subjects with other pleural cavity affections. As single markers, Apo CI's isoforms may currently not provide improved prediction success for MM cases. More research is needed to confirm the potential use of Apo CI as a candidate biomarker for inclusion as one of the variables in a positive decision tool for pleural mesothelioma diagnosis in individual effusion cases, next to cytology and SMRP analysis (MESOMARK assay) for this pathology.
